<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368273</url>
  </required_header>
  <id_info>
    <org_study_id>M2019482</org_study_id>
    <nct_id>NCT04368273</nct_id>
  </id_info>
  <brief_title>Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.</brief_title>
  <acronym>CCRT+PD-1</acronym>
  <official_title>Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of anti-PD-1 (toripalimab) combined with cisplatin
      concurrent IMRT for locally advanced cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose of toripalimab injection (pd-1 antibody) was 240mg/d, d1, i.v. every 14d, totally 4
      cycles (56 days)

      Concurrent chemoradiotherapy:

      Cisplatin 40 mg/m2 i.v., d1, administered once a week; Radiotherapy: pelvic intensity
      modulated radiotherapy, prescription dose DT: 50.4gy /2Gy/28f;After intraluminal irradiation
      DT: 30-36 Gy/6Gy/5-6f 2f/w, complete the radiotherapy within 56 days.

      Complete at least 4 cycles of concurrent chemoradiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of acute adverse events</measure>
    <time_frame>up to 3 months complete treatment</time_frame>
    <description>safety evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months later after treatment</time_frame>
    <description>efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>efficacy evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 antibody combined CCRT for patients with local advanced cervical cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 antibody</intervention_name>
    <description>a new treatment drug combined radical radiotherapy concurrent chemotharpy</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Toripalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HPV positive in patients with cervical squamous cell carcinoma confirmed by
             histopathology

          2. Patients with local advanced (2018FIGO staged IB3, IIA -IVA) cervical cancer and had
             not received any treatment before

          3. There are measurable lesions according to the efficacy evaluation criteria for solid
             tumors (RECIST) version 1.1

          4. ECOG score 0-2

          5. Expected survival ≥3 months

          6. LVEF≥55%

          7. Bone marrow function: neutrophils ≥1.5×109/L, platelets ≥100×109/L, hemoglobin ≥90g/L

          8. Liver and kidney functions: serum creatinine ≤1.5 times the upper limit of normal
             value;AST and ALT ≤2.5 times normal upper limit or ≤5 times normal upper limit in the
             presence of liver metastasis;Total bilirubin ≤1.5 times the upper limit of normal
             value, or ≤2.5 times the upper limit of normal value in patients with Gilbert's
             syndrome

          9. Thyroid function: normal range

         10. Non-lactating patients

         11. Sign the informed consent

        Exclusion Criteria:

          1. Patients with previous PD-1 or PD-L1 treatment

          2. Patients with previous abdominal or pelvic radiotherapy

          3. Other malignant tumors other than cervical cancer appeared in the past 5 years

          4. Immunosuppressive drugs were used within 4 weeks prior to the first study treatment,
             excluding nasal spray, inhaled or other local glucocorticoids or systemic
             glucocorticoids in physiological doses (i.e., no more than 10 mg/ day prednisone or
             equivalent doses of other glucocorticoids)

          5. Active, known, or suspected autoimmune disease (congenital or acquired)

             ), such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary
             inflammation, vasculitis, nephritis, thyroiditis, etc. (vitiligo or childhood asthma
             has been completely relieved, adults without any intervention can be included;Patients
             with type 1 diabetes with good insulin control can also be enrolled, as can
             hypothyroidism caused by autoimmune thyroiditis that requires hormone replacement
             therapy.)

          6. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic
             hematopoietic stem cell transplantation

          7. Known allergy to any component of the drug

          8. Serious medical diseases that are not under control, such as the combination of
             serious medical diseases, including severe heart disease, cerebrovascular disease,
             uncontrolled diabetes, uncontrolled hypertension,uncontrolled infection, active peptic
             ulcer

          9. Received other experimental drugs or participated in other drugs within 30 days of
             initial administration clinical research on the purpose of anticancer therapy

         10. Severe infection occurred within 4 weeks prior to study treatment, including, but not
             limited to, hospitalization hospital treatment of infection complications, bacteremia
             or severe pneumonia

         11. Human immunodeficiency virus (HIV) positive

         12. Hepatitis B surface antigen (HBsAg) positive, and the peripheral blood hepatitis B
             virus deoxygenation the titer of ribonucleic acid (HBV-DNA) was detected in subjects
             ≥1×10&lt;3&gt; IU/mL

         13. Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV)
             Antibody positive and HCV RNA positive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junjie Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University 3rd Hospital radiation oncology department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Jiang, MD</last_name>
    <phone>010-82266699</phone>
    <phone_ext>4912</phone_ext>
    <email>drjiangping@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University 3rd Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijng</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Junjie Wang</investigator_full_name>
    <investigator_title>Department director</investigator_title>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

